- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 285/12 - 1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
Patent holdings for IPC class C07D 285/12
Total number of patents in this class: 205
10-year publication summary
|
16
|
16
|
17
|
10
|
5
|
4
|
6
|
7
|
1
|
1
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Array BioPharma Inc. | 530 |
9 |
| Bristol-myers Squibb Company | 4883 |
8 |
| Oryzon Genomics S.A. | 105 |
5 |
| Reata Pharmaceuticals, Inc. | 122 |
5 |
| Receptos LLC | 66 |
5 |
| Toyama Chemical Co., Ltd. | 108 |
5 |
| The Arizona Board of Regents on Behalf of the University of Arizona | 2058 |
4 |
| The Lubrizol Corporation | 1310 |
4 |
| Omeros Corporation | 297 |
4 |
| Piramal Enterprises Limited | 158 |
4 |
| PRAECIS Pharmaceuticals Incorporated | 18 |
4 |
| Taisho Pharmaceutical Co., Ltd. | 860 |
4 |
| Merck Sharp & Dohme LLC | 3744 |
4 |
| Glaxo Group Limited | 4283 |
3 |
| Sanofi-Aventis Deutschland GmbH | 2603 |
3 |
| Board of Regents, The University of Texas System | 5610 |
3 |
| KYORIN Pharmaceutical Co., Ltd. | 175 |
3 |
| Ohio State Innovation Foundation | 1968 |
3 |
| Proteostasis Therapeutics, Inc. | 72 |
3 |
| PTC Therapeutics, Inc. | 475 |
3 |
| Other owners | 119 |